Rivia has secured $15 million in Series A funding, led by Earlybird with participation from Defiant and existing investors. This funding round follows the company's development of a data engine for clinical trial intelligence and will be used to launch a new suite of embedded AI agents, including Spark for data visualization and agents for proactive data quality monitoring. The company aims to address the increasing regulatory scrutiny and shrinking margins within drug development by improving clinical trial infrastructure.
